Dr. Anderson (coPI: Dr. Lukong) will study: "Regulation of PTEN in breast cancer cells".
Dr. Vizeacoumar will work on: "Exploiting the defective genome of cancer cells by synthetic lethality".
Dr. Xiang will develop a: "Novel HER2-specific T cell-based vaccine expressing potent Th epitope P30 for enhanced therapeutic immunity against trastuzumab-resistant HER2-positive breast cancer".
Share this story